1 Life Healthcare Inc ONEM
We take great care to ensure that the data presented and summarized in this overview for 1Life Healthcare Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ONEM
View all-
Addition Three General Partner, L.P. New York, NY2.65MShares$0100.0% of portfolio
-
Sarissa Consulting LLC Santa Monica, CA132KShares$02.33% of portfolio
-
S. Muoio & Co. LLC New York, NY80KShares$01.81% of portfolio
-
Havens Advisors LLC New York, NY50KShares$02.15% of portfolio
-
Telemetry Investments, L.L.C. New York, NY17.6KShares$00.46% of portfolio
-
Trustcore Financial Services, LLC2.5KShares$00.0% of portfolio
-
Covington Capital Management100Shares$00.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in ONEM
Top Purchases
Top Sells
About ONEM
1Life Healthcare, Inc. operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as third-party sponsorship. Its membership model includes seamless access to 24/7 digital health services paired with inviting in-office care routinely covered under health insurance programs. The company also offers administrative and managerial services pursuant to contracts with physician-owned professional corporations or One Medical Entities. As of December 31, 2021, it had 703,000 consumer and enterprise members, and 33,000 At-Risk members; 182 medical offices in 25 markets; and 8,500 enterprise clients in the United States. The company was incorporated in 2002 and is headquartered in San Francisco, California.
Insider Transactions at ONEM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Feb 22
2023
|
Lisa A Mango General Counsel and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
88,385
-100.0%
|
$1,590,930
$18.0 P/Share
|
|
Feb 22
2023
|
Amir Dan Rubin Chair, CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
99,748
-100.0%
|
$1,795,464
$18.0 P/Share
|
|
Feb 22
2023
|
Bjorn B Thaler Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,532
-100.0%
|
$387,576
$18.0 P/Share
|
|
Feb 22
2023
|
Vikas Agarwal Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,866
-100.0%
|
$159,588
$18.0 P/Share
|
|
Feb 22
2023
|
Andrew S Diamond Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,620
-100.0%
|
$425,160
$18.0 P/Share
|
|
Feb 22
2023
|
Scott C Taylor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,753
-100.0%
|
$139,554
$18.0 P/Share
|
|
Feb 22
2023
|
Holmes Kalen |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,534
-100.0%
|
$81,612
$18.0 P/Share
|
|
Feb 22
2023
|
David P Kennedy |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
250,779
-100.0%
|
$4,514,022
$18.0 P/Share
|
|
Feb 22
2023
|
David P Kennedy |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,285
-100.0%
|
$185,130
$18.0 P/Share
|
|
Feb 22
2023
|
Freda C Lewis Hall |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,534
-100.0%
|
$81,612
$18.0 P/Share
|
|
Feb 22
2023
|
Mary Ann Tocio |
SELL
Sale (or disposition) back to the issuer
|
Direct |
47,298
-100.0%
|
$851,364
$18.0 P/Share
|
|
Feb 22
2023
|
Paul R. Auvil Iii |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,586
-100.0%
|
$226,548
$18.0 P/Share
|
|
Feb 22
2023
|
Mark S. Blumenkranz |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,534
-100.0%
|
$81,612
$18.0 P/Share
|
|
Feb 22
2023
|
Bruce Dunlevie |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
665,257
-100.0%
|
$11,974,626
$18.0 P/Share
|
|
Feb 22
2023
|
Bruce Dunlevie |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,586
-100.0%
|
$226,548
$18.0 P/Share
|
|
Feb 17
2023
|
Lisa A Mango General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
6,150
-6.51%
|
$92,250
$15.32 P/Share
|
|
Feb 16
2023
|
Vikas Agarwal Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,117
-19.28%
|
$31,755
$15.36 P/Share
|
|
Feb 16
2023
|
Lisa A Mango General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
7,596
-7.44%
|
$113,940
$15.36 P/Share
|
|
Feb 16
2023
|
Bjorn B Thaler Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,015
-21.84%
|
$90,225
$15.36 P/Share
|
|
Feb 15
2023
|
Vikas Agarwal Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,132
+18.39%
|
-
|